ABEO — Abeona Therapeutics Inc.

Summary of ABEO Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $5.8 million for the year ended December 31, 2025, comprising:
  • License and Other Revenues: $3.4 million, primarily from a clinical milestone related to Rett syndrome.
  • Net Product Revenue: $2.4 million, reflecting the first commercial treatment of ZivaSkin in December 2025.
• Cost of Sales: $1.5 million, mainly from the first ZivaSkin treatment and costs related to a production batch that was not released due to sterility testing issues.
• R&D Expenses: Decreased to $26.8 million from $34.4 million in 2024, reflecting capitalized production costs post-approval.
• SG&A Expenses: Increased to $65 million, driven by commercial transition costs and personnel expenses.
• Net Income: $71.2 million, or $1.034 per basic share, a significant turnaround from a net loss of $63.7 million in 2024.
• Cash Position: $191.4 million as of December 31, 2025.

2. Strategic Updates and Business Highlights

• ZivaSkin Launch: Approved in April 2025, with commercial launch delayed to Q4 2025 due to sterility testing optimizations.
• Patient Demand: Over 100 potentially eligible patients identified, with two patients treated and three biopsied in Q4 2025.
• Qualified Treatment Centers (QTCs): Four centers activated, with plans to onboard five additional centers to expand patient access.
• Market Access: Major commercial payers have published coverage policies for ZivaSkin, covering approximately 80% of commercially insured lives and all Medicaid programs.

3. Forward Guidance and Outlook

• Patient Treatment Cadence: Expectation of one to two patients treated per month per QTC, with potential for increased capacity as centers gain experience.
• Profitability Goal: Achieving profitability is contingent on treating at least three patients per month, with confidence in reaching this target by mid-2026.
• R&D Spending: Anticipated to focus on registry studies and pipeline development, with a shift from R&D to SG&A as the company transitions to a commercial entity.

4. Bad News, Challenges, or Points of Concern

• Treatment Speed Variability: The speed at which identified patients receive treatment has varied significantly, which could impact revenue growth.
• Operational Challenges: The onboarding process for new QTCs is lengthy and complex, potentially delaying patient access.
• Sterility Testing Issues: Previous challenges with sterility testing raised concerns about manufacturing reliability, although management expressed confidence in resolving these issues.

5. Notable Q&A Insights

• QTC Onboarding: Management indicated that while they aim for seven active QTCs by the end of 2026, the onboarding process is complex and may lead to delays.
• Patient Treatment Timeline: The average timeline from patient identification to treatment is currently four to five months, but improvements are expected as processes become more efficient.
• Reimbursement Insights: Payers are generally supportive of ZivaSkin, with no significant restrictions on retreatment observed, which is encouraging for future patient access.
• Feedback from Patients and Physicians: Limited feedback available due to the small number of treated patients, but initial reports indicate positive experiences.

Overall, Abeona Therapeutics is positioned for growth with the launch of ZivaSkin, though it faces operational and market access challenges that need to be addressed to achieve its long-term goals.